NEW YORK — A blockbuster cancer treatment failed in a key study as the drug’s maker, Bristol-Myers Squibb, attempts to extend its usage for lung cancer patients. Shares of the Princeton, New Jersey, company plunged 17 percent when trading opened Friday. Shares of rival Merck & Co., which makes a rival cancer drug, spiked 8
